直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Expert Declaration’s Verbatim Repetition of Conclusory Attorney Argument Entitled to Little Weight

April 18, 2023

Authored and Edited by Li Zhang, Ph.D.; Umber Aggarwal; Amanda K. Murphy, Ph.D.

In Xerox Corp. v. Bytemark, Inc,[1] Director Vidal initiated sua sponte Director Review of the Board’s decision denying institution of Xerox’s IPR, affirmed the Board’s ruling, and designated it as precedential. The decision highlights the importance of presenting evidence and technical reasoning in expert declarations to support petition arguments.

Xerox’s IPR challenged U.S. Patent No. 10,360,567 (the ’567 patent), which claims a mobile ticketing system that detects fraudulent ticket activity by identifying mismatches between transmitted and received ticket data. Specifically, the claims recite a system that detects a user’s fraudulent activity and stores the occurrence of such activity as a “data value” in the data record associated with the user’s account.

In challenging the ’567 patent claims, Xerox asserted a reference called Terrell, which disclosed that, upon the detection of fraudulent activities, ticket purchasers “could be blocked from further use of the system.”[2] Xerox conceded that Terrell did not explicitly teach storing of a data value, as claimed in the ’567 patent, but argued that Terrell’s disclosure of blocking a ticket purchaser against potential fraud would either “require” storing such a data value or render such functionality obvious.[3] In support, Xerox relied on its expert’s declaration, which stated that a skilled artisan “would understand that [] blocking would require recording the blocking in a data record associated with that user’s account,” and “would find it obvious that blocking the account of the purchaser from further use of the system would include storing a data value indicating the fraudulent activity in a data record associated with the user account.”[4] The Board, however, determined the declaration testimony to merely repeat Xerox’s attorney argument verbatim, without providing any additional evidence or technical reasoning.[5] Consequently, the Board gave little weight to the expert testimony and denied institution.[6] Xerox requested rehearing and Precedential Opinion Panel (POP) review of the Board’s decision,[7] but Director Vidal initiated sua sponte Director Review, which dismissed the rehearing and POP request.[8]

The Director Review specifically addressed “the Board’s consideration of expert testimony.”[9] First, the Director rejected Xerox’s new obviousness arguments raised for the first time in its rehearing request that attempted to remedy the shortcomings of its petition, finding the arguments both untimely and lacking support in expert testimony.[10] Then, relying on Federal Circuit precedent, the Director determined that the Board was “correct in giving little weight” to the expert testimony because the “declaration merely offered conclusory assertions without underlying factual support and repeated, verbatim, [Xerox’s] conclusory arguments.”[11] In particular, the Director noted the expert’s declaration failed to “provide any technical detail, explanation, or statements” as to why Terrell’s disclosure about blocking a user required or rendered obvious storage of a data value in the data record associated with the user’s account, as recited in the ’567 patent claims.[12] The Director found that, rather than “setting forth facts and evidence in support of [Xerox’s] assertions,” the expert testimony merely “set[] forth [Xerox’s] conclusory assertions as though they [were] facts.”[13] Thus, the Director agreed with the Board that the expert declaration “is conclusory and unsupported, adds little to the conclusory assertion for which it is offered to support, and is entitled to little weight.”[14]

Take Away

The Board may give little to no weight to expert declarations that merely restate conclusory attorney argument verbatim without supporting evidence and technical reasoning.

Endnotes

[1] No. IPR2022-00624, Pap. No. 12 (PTAB Feb. 10, 2023) (Vidal, Dir.).

[2] Xerox Corp. v. Bytemark, Inc., No. IPR2022-00624, 2022 WL 3648989, at *4 (PTAB Aug. 24, 2022).

[3] Id. at *5.

[4] Xerox, No. IPR2022-00624, Ex. 1003, at ¶ 54.

[5] Xerox, 2022 WL 3648989, at *6.

[6] Id. at *6-7.

[7] Xerox, No. IPR2022-00624, Pap. No. 10.

[8] Xerox, No. IPR2022-00624, Pap. No. 13.

[9] Xerox, No. IPR2022-00624, Pap. No. 12, at 2.

[10] Id. at 4-5.

[11] Id. at 5.

[12] Id.

[13] Id.

[14] Id.

Related Practices

Global IP Enforcement, Litigation, and Trials

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Consumer Goods and Services

Related Offices

Boston, MA

London

Washington, DC

Contacts

Li Zhang, Ph.D.
Associate
Boston, MA
+1 617 646 1648
Email
Umber Aggarwal
Associate
Reston, VA
+1 571 203 2423
Email
Amanda K. Murphy, Ph.D.
Partner
London
+44 (0)20 7864 2814
Email

Copyright © 2023 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

2027 ABA-IPL Section Annual Meeting – IPLSPRING

April 14-15, 2027

Arlington

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

IAM Live: Trade Secret Strategy USA

November 10, 2026

San Jose

Charitable

2026 ALYN Hospital Wheels of Love Ride

November 8-12, 2026

Northern District

Conference

2026 ANA Masters of Advertising Law Conference

November 2-4, 2026

Huntington Beach

Conference

Life Sciences Patent Network North America Fall 2026

November 2-3, 2026

San Francisco

Conference

2026 TIPA International Symposium

October 30, 2026

Taipei City

Seminar

Future IP UK

October 21, 2026

London

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP